Alejandra Carvajal - Oct 1, 2024 Form 4 Insider Report for Mersana Therapeutics, Inc. (MRSN)

Role
SVP, Chief Legal Officer
Signature
/s/ Alejandra Carvajal
Stock symbol
MRSN
Transactions as of
Oct 1, 2024
Transactions value $
-$27,150
Form type
4
Date filed
10/7/2024, 05:48 PM
Previous filing
Jan 17, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRSN Common Stock Options Exercise $0 +50K +182.46% $0.00 77.4K Oct 1, 2024 Direct F1
transaction MRSN Common Stock Sale -$16.2K -8.09K -10.45% $2.00 69.3K Oct 2, 2024 Direct F2, F3
transaction MRSN Common Stock Sale -$11K -5.6K -8.08% $1.96 63.7K Oct 3, 2024 Direct F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRSN Restricted Stock Unit Options Exercise $0 -50K -100% $0.00 0 Oct 1, 2024 Common Stock 50K Direct F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents shares of common stock received upon vesting of the restricted stock units ("RSUs") awarded to the Reporting Person on September 5, 2023.
F2 Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2023. The sale was effected through an automatic "sell to cover" transaction that did not represent a discretionary trade by the Reporting Person.
F3 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.82 to $2.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.92 to $2.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F5 Each RSU represents the contingent right to receive one share of common stock of the Issuer.
F6 Fully vested as of October 1, 2024.